| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 7827.3 | 8276.9 | 7047.5 |
| Other income | 126.8 | 130.3 | 90.0 |
| Total income | 7954.1 | 8407.2 | 7137.5 |
| Profit before exceptional items & tax | 1579.6 | 2017.4 | 2007.0 |
| Profit before tax | 1579.6 | 2017.4 | 2007.0 |
| Net profit | 1155.3 | 1417.0 | 1484.8 |
| Operating margin | 19.9% | 24.0% | 28.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -22.20% |
|---|---|
| Net profit, quarter on quarter | -18.50% |
| Revenue, year on year | +11.10% |
| Operating profit, year on year | -24.20% |
| Operating profit, quarter on quarter | -23.00% |
NSE results filing, NSE: LUPIN. Figures extracted from the filing.
Lupin Ltd: key numbers
- Share price
- ₹2,015.90
- Market cap
- ₹92,186 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 16.7×Sector 41.3×
- Promoter holding
- 46.84%-0.01% QoQ
- FII holding
- 23.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lupin Ltd
All →Lupin Investor Presentation: Key Takeaways
Q2 FY27 net sales ₹77,855mn (+14% YoY); EBITDA ₹19,574mn, margin 25.1% (vs 31.3%); net income ₹11,553mn (-21.8% YoY). US pressured by competition/LOE.
Lupin Management Change
Lupin appointed Akhil Gupta as an Additional and Independent Director effective 3 November 2026, for five years to 2031. The appointment is subject to shareholder approval.
Lupin Product Launch
Lupin launched generic Raltegravir Tablets 600 mg in the United States. It is first-to-file, with 180-day exclusivity.
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.
Lupin Business Update
Lupin Limited disclosed that the U.S. FDA concluded an inspection at its Goa manufacturing facility, closing with a Form-483 containing one observation. The company will respond within the stipulated timeframe.
Lupin Management Change
Lupin Limited appointed Mr. Brian Savage as President and Chief Legal Officer, effective October 22, 2026. He will oversee global legal, compliance, and IP functions.